Altaire Pharmaceuticals Recalls Multiple Ophthalmic Products

News
Article

Altaire is voluntarily recalling ophthalmic products because of concerns regarding quality assurance controls in the manufacturing facility.

Altaire Pharmaceuticals, Inc. announced on July 15, 2019 that it was voluntarily recalling specific over-the-counter and prescription lots of multiple ophthalmic products manufactured and distributed under the Altaire label because of concerns regarding quality assurance controls. According to the company, management initiated the recall, and FDA has determined there may be a lack of sterility assurance. The company states the recall, which is being carried out to the retail level, is a precautionary measure, and it has not received any reports of adverse events in relation to the recalled products.

Detailed information regarding each recalled product, included lot number and expiration date, can be found on FDA’s website. Adverse events may be report to FDA through the agency’s MedWatch program.

Source: FDA

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content